Leyden Labs

Leyden Labs is a clinical-stage biotechnology company headquartered in Leiden, The Netherlands, with a regional office in Singapore, developing intranasal antibody products that protect people against known and newly emerging respiratory viruses. Its approach pairs mucosal immunity — delivering antibodies directly into the nasal passages, the gateway respiratory viruses use to enter the body — with broad protection, by targeting conserved regions of viral proteins so a single product can cover circulating strains and future variants. Its lead program, PanFlu, is an intranasal antibody candidate in clinical trials derived from CR9114, among the most broadly neutralizing influenza antibodies identified to date. Founded in 2021 by Koenraad Wiedhaup and Ronald Brus with founding scientist Jaap Goudsmit, the company is backed by GV and the SoftBank Vision Fund alongside the European Innovation Council Fund, the European Investment Bank and Invest-NL. Leyden Labs publishes no public developer program, API, or SDK; this profile captures its public web, security and identity surface for the API Evangelist network.

Leyden Labs is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and Immunology.

Leyden Labs’ developer surface includes engineering blog, YouTube channel, and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesBiotechnologyPharmaceuticalsImmunologyInfectious DiseaseVaccinesAntibodiesRespiratory HealthClinical TrialsNetherlands

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.2/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/leyden-labs: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Learn 1

Tutorials, courses, talks, and written guidance

YouTube

YouTube

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 5

The organization behind the API

Website

Blog

BlogRSS

Careers

LinkedIn

Other 2

Properties that don't map to a standard resource type

Publications

Publications

Events

Events

Source (apis.yml)

aid: leyden-labs
name: Leyden Labs
description: Leyden Labs is a clinical-stage biotechnology company headquartered in Leiden, The Netherlands, with a regional
  office in Singapore, developing intranasal antibody products that protect people against known and newly emerging respiratory
  viruses. Its approach pairs mucosal immunity — delivering antibodies directly into the nasal passages, the gateway respiratory
  viruses use to enter the body — with broad protection, by targeting conserved regions of viral proteins so a single product
  can cover circulating strains and future variants. Its lead program, PanFlu, is an intranasal antibody candidate in clinical
  trials derived from CR9114, among the most broadly neutralizing influenza antibodies identified to date. Founded in 2021
  by Koenraad Wiedhaup and Ronald Brus with founding scientist Jaap Goudsmit, the company is backed by GV and the SoftBank
  Vision Fund alongside the European Innovation Council Fund, the European Investment Bank and Invest-NL. Leyden Labs publishes
  no public developer program, API, or SDK; this profile captures its public web, security and identity surface for the API
  Evangelist network.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://leydenlabs.com/wp-content/uploads/2021/03/LL-diap-RGB.jpg
url: https://raw.githubusercontent.com/api-evangelist/leyden-labs/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
- softbank-vision-fund
x-tier: profiled
x-tier-reason: portfolio-lead-no-public-api
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Immunology
- Infectious Disease
- Vaccines
- Antibodies
- Respiratory Health
- Clinical Trials
- Netherlands
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://leydenlabs.com
- type: Blog
  url: https://leydenlabs.com/news
- type: BlogRSS
  url: https://leydenlabs.com/feed
- type: Publications
  url: https://leydenlabs.com/publications
- type: Events
  url: https://leydenlabs.com/events
- type: Careers
  url: https://leydenlabs.com/careers
- type: PrivacyPolicy
  url: https://leydenlabs.com/privacy
- type: Contact
  url: mailto:info@leydenlabs.com
- type: LinkedIn
  url: https://www.linkedin.com/company/leydenlabs/
- type: YouTube
  url: https://www.youtube.com/channel/UCovjgTDGBe1wURh6QXW9Qcw
- type: DomainSecurity
  url: security/leyden-labs-domain-security.yml
- type: LLMsTxt
  url: llms/leyden-labs-llms.txt
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence